Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
September 13, 2026
September 13, 2026
AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:
* * *
Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant . . .
* * *
Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant . . .